|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
HUE045629T2
(hu)
|
2011-07-01 |
2020-01-28 |
Ngm Biopharmaceuticals Inc |
Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére
|
|
HUE042374T2
(hu)
|
2012-06-13 |
2019-06-28 |
Incyte Holdings Corp |
Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
|
|
BR112015000653A2
(pt)
*
|
2012-07-11 |
2019-11-05 |
Blueprint Medicines Corp |
compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
CA2892152A1
(en)
|
2012-11-28 |
2014-06-05 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
SG10202100667SA
(en)
|
2012-12-27 |
2021-02-25 |
Ngm Biopharmaceuticals Inc |
Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
AR094812A1
(es)
|
2013-02-20 |
2015-08-26 |
Eisai R&D Man Co Ltd |
Derivado de piridina monocíclico como inhibidor del fgfr
|
|
US9499522B2
(en)
|
2013-03-15 |
2016-11-22 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
|
US9321786B2
(en)
|
2013-03-15 |
2016-04-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
AU2014228746B2
(en)
*
|
2013-03-15 |
2018-08-30 |
Celgene Car Llc |
Heteroaryl compounds and uses thereof
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
NZ711376A
(en)
|
2013-03-15 |
2020-01-31 |
Sanofi Sa |
Heteroaryl compounds and uses thereof
|
|
KR102469849B1
(ko)
|
2013-04-19 |
2022-11-23 |
인사이트 홀딩스 코포레이션 |
Fgfr 저해제로서 이환식 헤테로사이클
|
|
EP3019491A4
(en)
|
2013-07-09 |
2016-12-21 |
Dana Farber Cancer Inst Inc |
KINASEHEMMER FOR THE TREATMENT OF DISEASES
|
|
RU2718876C2
(ru)
|
2013-08-23 |
2020-04-15 |
Ньюфарма, Инк. |
Некоторые химические соединения, композиции и способы
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
RS57542B1
(sr)
|
2013-10-17 |
2018-10-31 |
Blueprint Medicines Corp |
Kompozicije korisne za lečenje poremećaja povezanih sa kit-om
|
|
SG11201602069WA
(en)
|
2013-10-18 |
2016-04-28 |
Eisai R&D Man Co Ltd |
Pyrimidine fgfr4 inhibitors
|
|
AU2014338549B2
(en)
|
2013-10-25 |
2017-05-25 |
Novartis Ag |
Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
|
|
DK3395814T3
(da)
*
|
2013-10-25 |
2022-07-04 |
Blueprint Medicines Corp |
Hæmmere af fibroblastvækstfaktorreceptoren
|
|
RU2707531C2
(ru)
|
2013-10-28 |
2019-11-27 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Модели рака и соответствующие способы
|
|
WO2015108992A1
(en)
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
|
WO2015109285A1
(en)
|
2014-01-20 |
2015-07-23 |
Cleave Biosciences, Inc. |
FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
|
|
KR102489475B1
(ko)
|
2014-01-24 |
2023-01-20 |
엔지엠 바이오파마슈티컬스, 아이엔씨. |
결합 단백질 및 그의 사용 방법
|
|
CN106459034B
(zh)
|
2014-02-07 |
2018-01-12 |
普林斯匹亚生物制药公司 |
作为成纤维细胞生长因子受体抑制剂的喹诺酮衍生物
|
|
WO2015134210A1
(en)
|
2014-03-03 |
2015-09-11 |
Principia Biopharma, Inc. |
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
|
|
US10398758B2
(en)
|
2014-05-28 |
2019-09-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
|
|
US10456449B2
(en)
|
2014-06-16 |
2019-10-29 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
CN105017227B
(zh)
*
|
2014-07-08 |
2018-03-09 |
四川百利药业有限责任公司 |
N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物
|
|
KR102344105B1
(ko)
|
2014-08-18 |
2021-12-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
모노시클릭 피리딘 유도체의 염 및 이의 결정
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
EP3200786B1
(en)
|
2014-10-03 |
2019-08-28 |
Novartis AG |
Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
RU2729161C2
(ru)
|
2014-10-23 |
2020-08-04 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
|
|
WO2016073855A1
(en)
|
2014-11-07 |
2016-05-12 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
WO2016115412A1
(en)
*
|
2015-01-18 |
2016-07-21 |
Newave Pharmaceutical Llc |
Dual-warhead covalent inhibitors of fgfr-4
|
|
US10202365B2
(en)
|
2015-02-06 |
2019-02-12 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
|
|
US10947201B2
(en)
*
|
2015-02-17 |
2021-03-16 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
AU2016219822B2
(en)
|
2015-02-20 |
2020-07-09 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
MA41551A
(fr)
*
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9802917B2
(en)
|
2015-03-25 |
2017-10-31 |
Novartis Ag |
Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
|
|
JP6695353B2
(ja)
|
2015-03-25 |
2020-05-20 |
ノバルティス アーゲー |
Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
|
|
CN114984013A
(zh)
|
2015-03-25 |
2022-09-02 |
国立癌症研究中心 |
胆管癌治疗剂
|
|
EP3280708B1
(en)
|
2015-04-10 |
2021-09-01 |
Araxes Pharma LLC |
Substituted quinazoline compounds and methods of use thereof
|
|
SG10201810057UA
(en)
|
2015-04-14 |
2018-12-28 |
Eisai R&D Man Co Ltd |
Crystalline fgfr4 inhibitor compound and uses thereof
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
EP3298011B1
(en)
|
2015-05-22 |
2021-11-17 |
Principia Biopharma Inc. |
Quinolone derivatives as fibroblast growth factor receptor inhibitors
|
|
HRP20211249T1
(hr)
|
2015-06-03 |
2021-11-12 |
Principia Biopharma Inc. |
Inhibitori tirozin kinaze
|
|
JP6816100B2
(ja)
|
2015-07-16 |
2021-01-20 |
アレイ バイオファーマ、インコーポレイテッド |
ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
JP2018521076A
(ja)
|
2015-07-24 |
2018-08-02 |
ブループリント メディシンズ コーポレイション |
Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物
|
|
WO2017019957A2
(en)
|
2015-07-29 |
2017-02-02 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
JP6940480B2
(ja)
*
|
2015-08-11 |
2021-09-29 |
プリンシピア バイオファーマ インコーポレイテッド |
Ｆｇｆｒ阻害剤の合成方法
|
|
CA2995997A1
(en)
|
2015-08-26 |
2017-03-02 |
Blueprint Medicines Corporation |
Compounds and compositions useful for treating disorders related to ntrk
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10208024B2
(en)
|
2015-10-23 |
2019-02-19 |
Array Biopharma Inc. |
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
|
|
US10724102B2
(en)
|
2015-10-26 |
2020-07-28 |
Loxo Oncology, Inc. |
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
|
|
TWI787018B
(zh)
|
2015-11-02 |
2022-12-11 |
美商纜圖藥品公司 |
轉染過程重排之抑制劑
|
|
ES2871036T3
(es)
|
2015-11-09 |
2021-10-28 |
Ngm Biopharmaceuticals Inc |
Método para el tratamiento de trastornos relacionados con ácidos biliares
|
|
EA038635B9
(ru)
|
2015-11-16 |
2021-10-26 |
Араксис Фарма Ллк |
2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
|
|
KR20180081790A
(ko)
|
2015-11-19 |
2018-07-17 |
블루프린트 메디신즈 코포레이션 |
Ntrk 관련 장애의 치료에 유용한 화합물 및 조성물
|
|
WO2017104739A1
(ja)
|
2015-12-17 |
2017-06-22 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
乳がん治療剤
|
|
CN105669566A
(zh)
*
|
2016-03-09 |
2016-06-15 |
华东师范大学 |
一种医药中间体n-芳基喹唑啉-2-胺化合物的制备方法
|
|
UY37155A
(es)
|
2016-03-17 |
2017-10-31 |
Blueprint Medicines Corp |
Inhibidores de ret
|
|
PL3439663T3
(pl)
|
2016-04-04 |
2024-11-18 |
Loxo Oncology, Inc. |
Sposoby leczenia nowotworów wieku dziecięcego
|
|
SG11201808559PA
(en)
|
2016-04-04 |
2018-10-30 |
Loxo Oncology Inc |
Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
FI3442977T3
(fi)
|
2016-04-15 |
2023-09-26 |
Blueprint Medicines Corp |
Aktiviinireseptorin kaltaisen kinaasin estäjät
|
|
US11357769B2
(en)
|
2016-05-10 |
2022-06-14 |
Eisai R&D Management Co., Ltd. |
Drug combinations for reducing cell viability and/or cell proliferation
|
|
FI3800189T3
(fi)
|
2016-05-18 |
2023-07-31 |
Loxo Oncology Inc |
(s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin valmistaminen
|
|
KR20180002053A
(ko)
*
|
2016-06-28 |
2018-01-05 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
WO2018004258A1
(ko)
*
|
2016-06-28 |
2018-01-04 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US10227329B2
(en)
|
2016-07-22 |
2019-03-12 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
US10035789B2
(en)
|
2016-07-27 |
2018-07-31 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
EP3497087B1
(en)
|
2016-08-15 |
2021-11-10 |
Neupharma, Inc. |
Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer
|
|
AU2017315459B2
(en)
|
2016-08-26 |
2023-06-29 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
US10744139B2
(en)
|
2016-09-01 |
2020-08-18 |
Nanjing Transthera Biosciences Co. Ltd. |
Inhibitors of fibroblast growth factor receptor and use thereof
|
|
CN110022900A
(zh)
*
|
2016-09-08 |
2019-07-16 |
蓝图药品公司 |
成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
|
|
WO2018055503A1
(en)
|
2016-09-20 |
2018-03-29 |
Novartis Ag |
Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
|
|
EP3519402A1
(en)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
JOP20190077A1
(ar)
|
2016-10-10 |
2019-04-09 |
Array Biopharma Inc |
مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
|
|
WO2018072707A1
(zh)
*
|
2016-10-18 |
2018-04-26 |
保诺科技（北京）有限公司 |
芳香族醚类衍生物、其制备方法及其在医药上的应用
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
JP7394623B2
(ja)
|
2016-11-02 |
2023-12-08 |
ノバルティス アーゲー |
Ｆｇｆｒ４インヒビターおよび胆汁酸捕捉薬の組合せ
|
|
CN109952290B
(zh)
*
|
2016-11-17 |
2022-05-03 |
广东众生药业股份有限公司 |
Fgfr4抑制剂及其制备方法和应用
|
|
KR101812266B1
(ko)
|
2016-11-25 |
2017-12-27 |
한국과학기술연구원 |
4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용
|
|
EP3524603B1
(en)
*
|
2016-12-19 |
2022-06-08 |
Abbisko Therapeutics Co., Ltd. |
Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof
|
|
CN108239069B
(zh)
*
|
2016-12-26 |
2021-01-05 |
南京药捷安康生物科技有限公司 |
一种用于成纤维细胞生长因子受体的抑制剂及其用途
|
|
CN108264511B
(zh)
*
|
2017-01-03 |
2021-04-13 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和其在医药上的用途
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
ES2948194T3
(es)
|
2017-01-18 |
2023-09-01 |
Array Biopharma Inc |
Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
|
|
EP3573967A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
WO2018140514A1
(en)
*
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
CN108503593B
(zh)
*
|
2017-02-28 |
2021-04-27 |
暨南大学 |
2-氨基嘧啶类化合物及其应用
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
WO2018183712A1
(en)
|
2017-03-31 |
2018-10-04 |
Blueprint Medicines Corporation |
Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
|
|
CA3063440A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
|
US11279697B2
(en)
|
2017-09-05 |
2022-03-22 |
Bioardis Llc |
Aromatic derivative, preparation method for same, and medical applications thereof
|
|
TWI791053B
(zh)
|
2017-10-10 |
2023-02-01 |
美商亞雷生物製藥股份有限公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
|
|
TWI812649B
(zh)
|
2017-10-10 |
2023-08-21 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
JP7278273B2
(ja)
|
2017-10-18 |
2023-05-19 |
ブループリント メディシンズ コーポレイション |
アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン
|
|
JOP20180094A1
(ar)
|
2017-10-18 |
2019-04-18 |
Hk Inno N Corp |
مركب حلقي غير متجانس كمثبط بروتين كيناز
|
|
WO2019085894A1
(zh)
*
|
2017-10-30 |
2019-05-09 |
如东凌达生物医药科技有限公司 |
一类含氮稠环化合物及其制备方法和用途
|
|
TW201938169A
(zh)
|
2018-01-18 |
2019-10-01 |
美商亞雷生物製藥股份有限公司 |
作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
|
|
US11603374B2
(en)
|
2018-01-18 |
2023-03-14 |
Array Biopharma Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
|
JP6997876B2
(ja)
|
2018-01-18 |
2022-02-04 |
アレイ バイオファーマ インコーポレイテッド |
Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
|
|
WO2019154364A1
(zh)
*
|
2018-02-08 |
2019-08-15 |
南京明德新药研发有限公司 |
作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
|
|
SG11202007591RA
(en)
|
2018-03-28 |
2020-09-29 |
Eisai R&D Man Co Ltd |
Therapeutic agent for hepatocellular carcinoma
|
|
CA3096043A1
(en)
|
2018-04-03 |
2019-10-10 |
Blueprint Medicines Corporation |
Ret inhibitor for use in treating cancer having a ret alteration
|
|
CN110386921A
(zh)
*
|
2018-04-23 |
2019-10-29 |
南京药捷安康生物科技有限公司 |
成纤维细胞生长因子受体抑制剂化合物
|
|
EP3788046B1
(en)
|
2018-05-04 |
2025-12-10 |
Incyte Corporation |
Salts of an fgfr inhibitor
|
|
EP4309737A3
(en)
|
2018-05-04 |
2024-03-27 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
|
CN111868058B
(zh)
*
|
2018-05-25 |
2023-06-13 |
上海和誉生物医药科技有限公司 |
一种fgfr抑制剂、其制备方法和在药学上的应用
|
|
CN110577524B
(zh)
*
|
2018-06-07 |
2022-01-28 |
北京大学深圳研究生院 |
一种激酶选择性抑制剂
|
|
WO2019242689A1
(zh)
*
|
2018-06-22 |
2019-12-26 |
北京赛特明强医药科技有限公司 |
一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
|
|
CA3224985A1
(en)
|
2018-07-31 |
2020-02-06 |
Loxo Oncology, Inc. |
Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
|
|
EP3829580A1
(en)
|
2018-08-01 |
2021-06-09 |
Araxes Pharma LLC |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
CR20250050A
(es)
|
2018-09-05 |
2025-03-19 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
|
|
CA3111984A1
(en)
|
2018-09-10 |
2020-03-19 |
Array Biopharma Inc. |
Fused heterocyclic compounds as ret kinase inhibitors
|
|
KR102531596B1
(ko)
*
|
2018-09-14 |
2023-05-11 |
아비스코 테라퓨틱스 컴퍼니 리미티드 |
Fgfr억제제, 그 제조 방법 및 용도
|
|
CN110950867A
(zh)
*
|
2018-09-27 |
2020-04-03 |
首药控股(北京)有限公司 |
一种fgfr4激酶抑制剂及其制备方法和用途
|
|
CN111138459B
(zh)
*
|
2018-11-06 |
2022-10-18 |
南京圣和药业股份有限公司 |
Fgfr4抑制剂的光学异构体及其应用
|
|
KR102195348B1
(ko)
|
2018-11-15 |
2020-12-24 |
에이치케이이노엔 주식회사 |
단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
|
|
WO2020119606A1
(en)
*
|
2018-12-10 |
2020-06-18 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of fibroblast growth factor receptor
|
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
|
CN113490666A
(zh)
*
|
2018-12-19 |
2021-10-08 |
奥瑞生物药品公司 |
作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
|
|
WO2020177067A1
(en)
*
|
2019-03-05 |
2020-09-10 |
Bioardis Llc |
Aromatic derivatives, preparation methods, and medical uses thereof
|
|
CN113646314B
(zh)
*
|
2019-03-08 |
2023-12-08 |
首药控股(北京)股份有限公司 |
Fgfr4激酶抑制剂及其制备方法和用途
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
CN113966334B
(zh)
|
2019-04-12 |
2025-01-21 |
缆图药品公司 |
化合物(i)的晶体形式
|
|
CN110317176A
(zh)
*
|
2019-07-04 |
2019-10-11 |
沈阳药科大学 |
2-氨基嘧啶类化合物及其用途
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021018047A1
(zh)
|
2019-07-26 |
2021-02-04 |
南京明德新药研发有限公司 |
作为fgfr和vegfr双重抑制剂的吡啶衍生物
|
|
WO2021023192A1
(zh)
*
|
2019-08-08 |
2021-02-11 |
漳州片仔癀药业股份有限公司 |
吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
|
|
US11597722B2
(en)
|
2019-08-08 |
2023-03-07 |
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. |
Crystal form D of pyrazine-2(1H)-ketone compound and preparation method therefor
|
|
JP7121218B1
(ja)
|
2019-08-08 |
2022-08-17 |
▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 |
ピラジン－２（１ｈ）－オン系化合物の製造方法
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021076602A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN112759593A
(zh)
|
2019-11-01 |
2021-05-07 |
北京伯汇生物技术有限公司 |
桥环并醛基吡啶衍生物及其应用
|
|
KR20220131900A
(ko)
|
2019-12-04 |
2022-09-29 |
인사이트 코포레이션 |
Fgfr 억제제의 유도체
|
|
JP7720840B2
(ja)
|
2019-12-04 |
2025-08-08 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式複素環
|
|
EP4069369A4
(en)
|
2019-12-06 |
2024-02-14 |
Schrödinger, Inc. |
CYCLIC COMPOUNDS AND METHODS OF USE THEREOF
|
|
CA3162851A1
(en)
*
|
2019-12-23 |
2021-07-01 |
Qiang Zhang |
Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof
|
|
PH12022551523A1
(en)
|
2019-12-27 |
2024-01-29 |
SchraDinger Inc |
Cyclic compounds and methods of using same
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CA3183728A1
(en)
|
2020-05-29 |
2021-12-02 |
Blueprint Medicines Corporation |
Solid forms of pralsetinib
|
|
CN116096707A
(zh)
*
|
2020-06-05 |
2023-05-09 |
金耐特生物制药公司 |
成纤维细胞生长因子受体激酶的抑制剂
|
|
CN116490507A
(zh)
|
2020-09-10 |
2023-07-25 |
薛定谔公司 |
用于治疗癌症的杂环包缩合cdc7激酶抑制剂
|
|
CN112851587A
(zh)
*
|
2021-01-21 |
2021-05-28 |
药雅科技(上海)有限公司 |
一种用于治疗癌症的炔类杂环化合物及其制备方法与用途
|
|
JP2024505890A
(ja)
|
2021-01-26 |
2024-02-08 |
シュレーディンガー， インコーポレイテッド |
がん、自己免疫及び炎症性障害の治療に有用な三環式化合物
|
|
EP4286382A4
(en)
*
|
2021-01-26 |
2025-01-08 |
CGeneTech (Suzhou, China) Co., Ltd. |
CRYSTAL FORM OF A METHYLPYRAZOLE-SUBSTITUTED PYRIDOIMIDAZOLE COMPOUND AND METHOD FOR PREPARING THE SAME
|
|
CN114853740B
(zh)
*
|
2021-02-03 |
2023-08-01 |
药雅科技(上海)有限公司 |
炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途
|
|
TWI820622B
(zh)
*
|
2021-03-04 |
2023-11-01 |
美商美國禮來大藥廠 |
Fgfr3抑制劑化合物
|
|
WO2022194160A1
(zh)
*
|
2021-03-16 |
2022-09-22 |
上海启晟合研医药科技有限公司 |
非索替尼固体形式及其制备方法
|
|
TW202300150A
(zh)
|
2021-03-18 |
2023-01-01 |
美商薛定諤公司 |
環狀化合物及其使用方法
|
|
JP7738668B2
(ja)
*
|
2021-03-26 |
2025-09-12 |
ハンチョウ アペロア メディスン リサーチ インスティチュート カンパニー リミテッド |
ダブルリング雑環ｆｇｆｒ４阻害剤、ダブルリング雑環ｆｇｆｒ４阻害剤を含有する医薬組成物と製剤、及びその用途
|
|
CA3215903A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN113912602B
(zh)
*
|
2021-10-14 |
2023-05-05 |
温州医科大学 |
一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途
|
|
WO2024242495A1
(ko)
*
|
2023-05-25 |
2024-11-28 |
주식회사 매직불릿테라퓨틱스 |
단백질 키나아제 억제용 신규 화합물 및 이를 포함하는 약학조성물
|
|
TWI896159B
(zh)
*
|
2023-06-09 |
2025-09-01 |
大陸商上海和譽生物醫藥科技有限公司 |
一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
WO2025059027A1
(en)
|
2023-09-11 |
2025-03-20 |
Schrödinger, Inc. |
Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
|